英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Percina查看　Percina　在百度字典中的解释百度英翻中〔查看〕
Percina查看　Percina　在Google字典中的解释Google英翻中〔查看〕
Percina查看　Percina　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Nonstatin Cholesterol Medications - NEXLIZET® NEXLETOL®
    NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like stent placement or bypass surgery, in adults who were unable to take recommended statin treatment
  • Nexlizet: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Nexlizet (bempedoic acid and ezetimibe) may be used to reduce LDL-C levels in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), alone or in combination with other LDL-C lowering therapies It should be used i
  • NEXLIZET® NEXLETOL® HCP Information - Official Site
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Nexlizet (Bempedoic acid and Ezetimibe) for Heart Disease
    Overview Nexlizet is a prescription drug approved by the U S Food and Drug Administration (FDA) to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
  • FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
    U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
  • FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to . . .
    Esperion announced that the FDA approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
  • Nexlizet: Dosage, side effects, uses, interactions, cost, and . . .
    Dosage for reducing certain cardiovascular risks Nexlizet is approved to help reduce the risk of heart attack and coronary revascularization (a type of heart procedure) in certain adults
  • Nexlizet Patient Tips: 7 things you should know - Drugs. com
    The bempedoic acid component of Nexlizet also reduces the risk of a heart attack or revascularization procedures in statin-intolerant patients with or at risk for cardiovascular disease





中文字典-英文字典  2005-2009